Kornimate/medical-research-clean huggingface dataset:
a trial of fecal microbiome transplantation in parkinson's disease patients

Conditions: Parkinson Disease

Summary: 48 pd patients (age 35-75y; h\&y 1-3) testing positive in a stool pd-dysbiosis test will be randomized in a 2:1 ratio to receive either donor fmt or their own stool through intracaecal infusion. the main outcome measure will be the sum of mds-updrs i-iii at 6 months to cover motor and non-motor symptom changes. a wide array of secondary clinical outcome measures will be assessed longitudinally and a large array of measurements, biospecimens (stool, urine, blood, colonic biopsies), and imaging data will be collected for further analysis at baseline, 1, 6, and 12 months.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd (clinically probable pd) * h\&y off 1-3 at baseline visit exclusion criteria: 1. chronic gastrointestinal disease (ibs allowed, celiac disease allowed if on gluten free diet, gastritis allowed) 2. any previous major gastrointestinal surgery that may alter gastrointestinal physiology 3. any abdominal surgery in the last 3 months 4. major genital and/or rectum prolapse 5. active autoimmune disease 6. active cancer within 5 years (allowed: basalioma and successfully removed carcinoma in situ) 7. immune deficiency 8. hiv infection 9. antibiotic use in last 3 months before baseline visit 10. dementia as indicated by moca \<21p 11. psychosis 12. active significant impulse control disorder (by interview and medical records) 13. major depression as indicated by bdi-ii \>28 14. pregnancy 15. alcohol or drug abuse 16. negative dysbiosis test result 17. iodine allergy 18. deep brain stimulation or duodopa/lecigon treatment 19. inability to interrupt regular use of nsaids for at least one month before permeability assessments

Keywords: parkinson's disease fmt microbiota gut-brain axis
clinical prediction model for in-hospital rebleeding in acute non-variceal upper gastrointestinal bleeding

Conditions: Acute Non-variceal Upper Gastrointestinal Bleeding

Summary: anvugib is a serious condition that can cause symptoms like vomiting blood or passing black stools. although treatments have improved, about 10% to 30% of patients experience rebleeding shortly after their initial treatment, which increases the risk of death. currently, doctors use tools like the glasgow-blatchford score, rockall score, and aim65 score to predict how patients with anvugib might recover. however, these tools are not very effective at identifying patients who are at risk for rebleeding. this study aims to create a new, more accurate prediction model to help doctors identify high-risk patients earlier. the investigators believe that a new predictive model, which combines patient symptoms, lab test results, and imaging findings, will improve the ability to identify patients at high risk of rebleeding compared to existing tools.the goal is to provide doctors with a more reliable tool to guide their decisions, such as when to give preventive treatments or increase monitoring. this could lead to better outcomes and reduce the risk of complications or death. this study uses patient data collected during routine care to develop and test the new model, ensuring the findings are directly applicable to real-world clinical settings.


Eligibility criteria:
inclusion criteria: * age exceeding 18 years, * clinical diagnosis of acute non-variceal upper gastrointestinal bleeding , * patients who underwent endoscopy within 24 hours of admission with confirmation of non-variceal bleeding exclusion criteria: * upper gastrointestinal bleeding during hospitalization; * transfer from other hospitals; * variceal bleeding; * lower gastrointestinal bleeding.; * bleeding attributed to systemic diseases like disseminated intravascular coagulation (dic) and hematological disorders; * patients with incomplete clinical data or laboratory test results; * patients who either requested early discharge or declined gastroscopy.

Keywords: rebleeding acute non-variceal upper gastrointestinal bleeding
bone regenerative techniques in endodontic microsurgery

Conditions: Apical Periodontitis

Summary: the purpose of this randomized controlled clinical trial was to evaluate two dimensionally and 3-dimensionally the effect of resorbable collagen-based bone filling material on periapical healing following endodontic microsurgery (ems) on endodontic lesions presenting four-wall defect.


Eligibility criteria:
inclusion criteria: * healthy adult. * intact coronal restoration with no sign of leakage. * class b (small lesion) and c (large lesion) periapical lesions. (kim and kratchman 2006) exclusion criteria: * patients with medical conditions and contraindications to surgery. * minors. * pregnancy. * teeth with signs of coronal leakage. * teeth with vertical root fractures.

Keywords: persistent periapical pathology
computer assisted vasopressor titration in critically ill patients

Conditions: Closed-Loop Communication

Summary: the purpose of this pilot study is to evaluate the performance of a novel closed-loop (automated) vasopressor administration system that delivers norepinephrine using feedback from standard operating room hemodynamic monitor (ev1000 monitor-flotrac edwards lifesciences, irvine, usa) in 10 to 12 critically ill patients in the intensive care unit.

the investigators have developed an automated closed-loop system for vasopressor administration . they will test it in critically ill patients. the investigators want to demonstrate that the closed-loop system can maintain mean arterial pressure ( map) within a very narrow range (within +/- 5 mmhg of the predefined map target) for more than 85 % of the treatment time. the investigators have shown this to be the case in simulation studies and in-vivo animal studies and in surgical patients but not yet in the intensive care unit (icu). investigators will recruit 10 to 12 icu patients equipped with a mini-invasive cardiac output monitoring and under continuous norepinephrine infusion. these patients will typically include: septic patients, neuro icu patients, ards patients, trauma patients or postoperative patients. the target map will be determined by the icu physician in charge of the patient. fluids will be given standard of care. the closed loop (automated) system will use an infusion pump (q-core and chemyx pump) and a controller (a computer run index and algorithm developed by sironis) to make frequent, regular and accurate adjustments of vasopressor (norepinephrine) the goal is to register a period of two hours of closed-loop control of map.

Eligibility criteria:
inclusion criteria: - icu patients under norepinephrine administration and equipped with a advanced hemodynamic monitoring device exclusion criteria: * subjects under 18 years of age * subjects not requiring cardiac output monitoring or an arterial line * subject with atrial fibrillation * subjects who are pregnant
dcb versus primary selective stenting in tasc c/d femoropopliteal artery disease

Conditions: Safety Issues; Efficacy, Self

Summary: this study aims to compare the mid- and long-term outcomes between paclitaxel-coated balloon and primary selective stenting in the treatment of tasc c/d femoropopliteal artery occlusive disease.


Eligibility criteria:
inclusion criteria: * subject age 18-85yrs. * subject has been informed of the nature of the study, agrees to participate, and has signed a medical ethics committee approved consent form. * subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing. * rutherford category 2-5. * subject has a de novo tasc c/d femoropopliteal artery lesions which does not exceed to the segment p1 of popliteal artery. * the total length of target lesion ≤30cm. * reference vessel diameter \>4 mm and \<6.5 mm by visual assessment. * patent inflow artery with stenosis \<30% and at least 1 infrapopliteal artery to the ankle (\<50% diameter stenosis). * a guidewire has successfully traversed the target treatment segment. exclusion criteria: * acute thrombus in the target vessels. * vessel stenosis or occlusion due to buerger's disease or autoimmune arteritis. * subject received prior stents implantation with in-stent restenosis or occlusion. * reintervention of the target lesion \<90 days before the study procedure. * acquired thrombophilia or uncontrolled hypercoagulation states. * life expectancy \<12 months. * severe renal（scr≥2.5 mg/dl）or hemodialysis dependence. * pregnancy, suspected pregnancy, or breastfeeding during study period. * contraindication to contrast media or any study-required medication (antiplatelet, anticoagulant, or thrombolytic agents, etc.). * hypersensitivity to nitinol and/or paclitaxel.
bortezomib for the treatment of refractory rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a single-center, single-arm, prospective study on the efficacy and safety of bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: 1. age between 18\~70 years. 2. fulfilling the 2010 acr/eular classification criteria for ra. 3. failed to at least two bdmards (including but not limited to tnf inhibitors, il-6 receptor inhibitors, t cell costimulation inhibitor and anti-b cell biologics) or tsdmards (including but not limited to jak inhibitors) in combination with a csdmard for at least 12 weeks. the dosage of cs/b/tsdmards needs to be stable for at least 6 weeks. 4. for patients receiving glucocorticoids, the dosage of gc needs to be less than or equal to 10mg prednisone equivalent and stable for at least 6 weeks. 5. for patients receiving non-steroid anti-inflammatory drugs, the dosage of nsaid needs to be stable for at least 2 weeks. 6. neutrophil≥1.0×10\^9/l, platelet≥100×10\^9/l, alanine transaminase (alt) and aspartate aminotransferase (ast) within 3 uln, total bilirubin within 1.5 uln. 7. informed consent obtained. exclusion criteria: 1. other concomitant autoimmune diseases (except for sjogren's syndrome secondary to rheumatoid arthritis). 2. the presence of severe uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neuropsychiatric disorders, or abnormal laboratory tests. the investigators consider that participation in the study may make unacceptable risks to the subjects. 3. a history of malignancy with a clinical cure time of less than 5 years. 4. pregnant or breast-feeding women, or planning to get pregnant or start breastfeeding during the study. 5. vaccinated with live attenuated virus within 4 weeks before entering the study. 6. allergic to bortezomib or mannitol. 7. participated in any other investigational drug trial within 12 weeks before study initiation. 8. active hepatitis or liver disease at the time of screening: hepatitis b surface antigen (hbsag) or anti-hepatitis c virus antibodies (hcvab) positive; (note: if hepatitis b core antibody, (hbcab) is positive and hbsag is negative, hbv-dna detection will be performed, patient is eligible if hbv-dna was negative). 9. active herpes zoster infection, or severe infection requiring intravenous antibiotics or hospitalization occurred 12 weeks before study initiation. 10. other conditions that not suitable for inclusion in the study, assessed by the investigators.

Keywords: rheumatoid arthritis bortezomib
biotin deficiency and restless legs syndrome

Conditions: End Stage Renal Disease; Restless Legs Syndrome

Summary: restless leg syndrome (rls) is a common neuropathic disorder in patients with end stage renal disease (esrd). study design: because micronutrient depletion has been associated with rls in esrd and because the vitamin biotin is dialyzable, the investigators examined the relationship between biotin status and rls in esrd. objectives: to assess the prevalence of biotin deficiency in those with and without rls (study 1) and to determine the effect of biotin supplementation on rls symptoms (study 2) in patients receiving chronic dialysis due to esrd.

setting and participants: esrd patients receiving chronic dialysis as outpatients at saint patrick hospital in missoula, montana.

Eligibility criteria:
inclusion criteria: * esrd requiring hemodialysis or peritoneal dialysis therapy for a duration of at least 3 months. exclusion criteria: * history of consumption of more than 300 micrograms daily of biotin * oral contraceptive therapy containing high amounts of estrogen because studies in rats provide evidence that high doses of steroid hormones reduce biotin status {wang, 1997 #1634} * women of childbearing age because of concern that biotin deficiency may be teratogenic {mock, 2009 #2568}.

Keywords: biotin restless kidney dialysis renal
dendritic cell vaccination in melanoma patients scheduled for regional lymph node dissection

Conditions: Melanoma Stage III or IV

Summary: dendritic cells (dcs) are the professional antigen-presenting cells of the immune system. as such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have been observed. for these therapies accurate delivery to target organs is essential. correct delivery and subsequent migration of vaccinated dcs to regional lymph nodes is of paramount importance for effective stimulation of the immune system. currently it is not known what the best route of administration is for dc vaccines. using magnetically labeled dcs, we investigate the potential of mri cell tracking to monitor dc therapy. this is investigated in stage iii/iv melanoma patients in whom a regional lymph node dissection is scheduled. autologous monocyte-derived dcs are labeled with the clinically approved superparamagnetic iron oxide (spio) formulation endorem and 111in-oxine and injected either in the skin or directly in lymph nodes under ultrasound guidance. two days after vaccination patients are monitored with scintigraphy and mr imaging. lymph nodes are then resected. subsequently patients receive 3 more vaccination with dcs. during and after therapy immune responses against the used melanoma peptides are monitored.


Eligibility criteria:
inclusion criteria: histologically documented evidence of melanoma stage iii-iv melanoma according to the 2001 ajcc criteria radical lymph node dissection planned, either with curative (stage iii) or palliative (stage iv) intent melanoma expressing gp100 (compulsory) and tyrosinase (non-compulsory) hla-a2.1 phenotype according to lymphocyte hla typing ecog performance status 0-1, life expectancy \> 3 months age 18-75 years interval since last prior chemotherapy, immunotherapy or radiotherapy at least 4 weeks, no residual toxicity of prior treatment. wbc \> 3.0 x 109/l, lymphocytes \> 0.8 x 109/l, platelets \> 100 x 109/l, serum creatinine \< 150 μmol/l, serum bilirubin \< 25 μmol/l written informed consent expected adequacy of follow-up exclusion criteria: no clinical signs of cns metastases, in patients with a clinical suspicion of other metastases diagnostic tests should be performed to exclude this. no concomitant use of corticosteroids or other immunosuppressive agents no history of second malignancy within the last 5 years. adequately treated basal carcinoma of skin or carcinoma in situ of cervix is acceptable within this period no serious concomitant disease, no active infections. no autoimmune disease or organ allografts, no clinical suspicion of hiv or hepatitis b no contra-indications for mri-scanning: claustrophobia, pacemaker or pacemaker threads, cerebral clips or artificial heartvalves, internal hearing prosthesis no known allergy to shell fish (contains klh) no pregnant or lactating women

Keywords: dendritic cells immunotherapy vaccination melanoma peptides mri scintigraphy immune response
positive surgical margins rate and egfr family members expression in prostate cancer treated with bicalutamide

Conditions: Prostate Cancer

Summary: following radical prostatectomy (rp), about 20% to 40% of the patients with prostate cancer (pca) exhibit pathological parameters which are associated with a high risk of disease recurrence. the rationale for nht is based on the theory that androgen ablation induces pca apoptosis which induces a regression of the primary tumor bulk before rp. however the use of nht prior rp is highly controversial. in spite of these unenthusiastic results, the relative short time of treatment and the use of different drugs from those utilized in other trials might still to make this regimen attractive in terms of drug related side effects and effectiveness. in this regard, bicalutamide presents unique characteristics since it work differently respect to other anti-hormonal agents by interfering on both genotropic and non-genotropic mechanisms of androgen receptor


Eligibility criteria:
inclusion criteria: * patients with ct2-t3a prostate cancer exclusion criteria: * men\>75 years * men\<18 years * prior hormonal therapy * prior radiation or chemotherapy * prior investigational agents * life expectancy \> 10 years * prior malignancy within the last five years * any other serious medical or psychiatric condition
myofascial release and kinesio taping on autonomic nervous system in low back pain

Conditions: Low Back Pain; Chronic Disease

Summary: the purpose of this current randomized clinical trial is to determine the effects of myofascial soft tissue release and kinesio taping on disability, pain, quality of life, autonomic nervous system and oxidative stress indicators in chronic low back pain.

design: randomized clinical trial. objective: to determine the effects of myofascial soft tissue release and kinesio taping on pain, disability, quality of life, and autonomic nervous system indicators. methods and measures: sixty-four individuals will be randomly assigned to one of two groups. intervention: for 10-week, the group 1 will undergo treatment comprising a myofascial soft tissue release protocol (1/week) and the group 2 will recieve a kinesio taping treatment (1/week). main outcome measures: intensity of pain, disability, quality of life, biochemical stimation intertitial fluid, body mass indicators, hormonal indicators, indicators of autonomic nevous system, and indicators of oxidative stress will be collected in both groups at baseline, 10 weeks and 15 weeks after the last intervention. baseline demographic and clinical variables will be examined between both groups with an independent student t-test for continuous data. separate 2x3 model anova with time (baseline, 10 weeks and 15 weeks) as the within-subjects factor, group will be to determine the effects of the treatment.

Eligibility criteria:
inclusion criteria: * score ≥ 4 on the roland morris disability questionnaire. * low back pain for ≥ 3 months. * not undergoing another physical therapy treatment. exclusion criteria: * disease of the central or peripheral nervous system. * having previously undergone manual therapy. * contraindication to low back manual therapy. * a history of spinal surgery. * treatment with corticosteroid in the past two weeks. * clinical sign of radiculopathy * presence of stenosis

Keywords: low back pain chronic pain manual therapy randomized clinical trial bandages
characteristics and limitations of intraoperative oct supported membrane peeling in macular diseases

Conditions: Macular Diseases

Summary: during the last decade optical coherence tomography (oct) extended the possibilities for in vivo macula diagnostic and was increasingly used for pre- and post-operative imaging of retinal diseases. spectral-domain optical coherence tomography (sd-oct) with its increased scanning speed and image-resolution provides more detailed information of microstructures in the macula. epiretinal membrane (erm), lamellar macular hole, macular hole and vitreomacular traction syndrome are disorders involving the posterior pole of the eyeball with consecutive vision loss. in patients with loss of vision and metamorphopsia disturbing their lifestyle, vitrectomy and membrane peeling is usually performed to remove traction and the erm. different study groups showed that intraoperative use of sd-oct is possible and improves the quality of peeling surgery.

the aim of the study is to assess the benefits and limits of intraoperative oct (i-oct), for example whether i-oct assisted membrane peeling is possible without use of dyes for enabling better localistion of the erm during surgery and to compare that scheme with different "gold standard" dyes for peeling such as membrane blue dual and triamcinolone. rationale for that study is to work out which setting enables best visualisation of erm and ilm (ilm) in i-oct. a limitation of that method seems to be visualisation of the inner limiting membrane, so that dying of the ilm will probably be still necessary in all cases where ilm-peeling is sheduled.

Eligibility criteria:
inclusion criteria: * epiretinal membrane, lamellar hole of the macula, macular hole and vitreomacular traction syndrome exclusion criteria: * other diseases of the eye, such as amd, retinopathia pigmentosa

Keywords: epiretinal membrane lamellar holes of the macula macular holes vitreomacular traction syndrome
swallowing training in parkinson's disease

Conditions: Parkinson's Disease; Deglutition Disorders; Voice Disorders

Summary: dysphagia in parkinson's disease(pd) is common and its presence is related to motor and sensory abnormalities, and incoordination between swallowing and breathing. despite harming as respiratory infections and increased risk of death, treatment of this condition remains uncertain. this study aims to evaluate the effect of oral motor exercises on the swallowing dynamics and quality of life of dysphagic parkinson's disease patients. this study is an open trial, self-paired and blinded to the examiner. the participants will perform oropharyngeal exercises for five weeks and will be evaluated before and after intervention by swallowing videofluoroscopy and questionnaires about quality of life in dysphagia (swal-qol).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson disease * complaint of dysphagia exclusion criteria: * hoehn and yahr stage 5 * other neurological conditions * therapy for swallowing in the last 3 months * cognitive disorders * psychiatric disorders

Keywords: parkinson's disease dysphagia treatment
the osteostrand plus deformity study

Conditions: Spinal Fusion

Summary: a clinical study evaluating outcomes for patients with spinal deformity.

a clinical study evaluating deformity patients treated with demineralized bone matrix as compared to patients treated with bone morphogenetic protein.

Eligibility criteria:
inclusion criteria: -≥18 years of age * indicated for deformity correction surgery * require spinal fusion at four or more levels * are willing to return for follow-up visits * willing to sign the informed consent forms exclusion criteria: * uncontrolled diabetes * morbid obesity * history of alcohol or drug abuse * corticosteroid use * fever or leukocytosis * systemic infection * active malignancy * elevation of white blood cell count * osteoporosis * disease of bone metabolism * unsuitable or insufficient bone support * skeletal immaturity * prior fusion * use of steroids, immune suppressants, osteoporosis medications * use of internal bone stimulators * institutionalized or a prisoner * undergoing (undergone) a worker's compensation case * pregnancy (includes women who are currently pregnant, lactating or wishing to become pregnant during the study duration) * participation in another research study involving another implant, product or drug that may affect the outcomes of this clinical study within the last 30 days, or planned during this clinical study * any other condition that the investigator determines is unacceptable for enrollment into this clinical study